HER2 overexpression or amplification is identified in approximately 15–20% of breast cancers [6,7] and is associated with higher histologic grade and stage, increased metastatic potential, decreased overall survival (OS), resistance to endocrine therapy and poor response to selected chemotherapy [8,9]. The gene discussed is ERBB2; the disease is breast cancer.